TY - JOUR
T1 - Adverse birth outcomes in adolescent and young adult female cancer survivors
T2 - a nationwide population-based study
AU - Kao, Wei Heng
AU - Kuo, Chang Fu
AU - Chiou, Meng Jiun
AU - Liu, Yu Cheng
AU - Wang, Chun Chieh
AU - Hong, Ji Hong
AU - Hsu, Jun Te
AU - Chiang, Yu Jung
AU - Chuang, Yi Fang
N1 - Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Cancer Research UK.
PY - 2020/3/17
Y1 - 2020/3/17
N2 - Background: For female adolescent and young adult (AYA), cancer with treatments may affect their children’s health. Our aim was to determine reliable risk estimates of adverse birth outcomes in AYA cancer survivors and the differential effects of treatments. Methods: The study population of 4547 births in the AYA cancer survivor group and 45,463 in the comparison group were identified from two national databases between 2004 and 2014. Detailed maternal health conditions, such as maternal comorbidities, medication use during pregnancy and lifestyles, were adjusted in the statistical analyses. The outcomes included low birth weight, preterm labour, stillbirth, small or large for gestational age, a 5-min Apgar score <7, congenital malformation and foetal distress. Results: The AYA cancer survivor group had a 9% higher risk of overall adverse birth outcomes (adjusted odds ratio, 1.09; 95% confidence interval, 1.02–1.16), especially low birth weight and preterm labour than the comparison group. The radiotherapy-only group additionally had a higher risk of foetal distress, and a 5-min Apgar score <7. Conclusion: AYA cancer survivors, especially those who have received radiotherapy, still have higher risks of adverse birth outcomes after adjusting for detailed maternal health conditions. Preconception counselling and additional surveillance may be warranted in this population.
AB - Background: For female adolescent and young adult (AYA), cancer with treatments may affect their children’s health. Our aim was to determine reliable risk estimates of adverse birth outcomes in AYA cancer survivors and the differential effects of treatments. Methods: The study population of 4547 births in the AYA cancer survivor group and 45,463 in the comparison group were identified from two national databases between 2004 and 2014. Detailed maternal health conditions, such as maternal comorbidities, medication use during pregnancy and lifestyles, were adjusted in the statistical analyses. The outcomes included low birth weight, preterm labour, stillbirth, small or large for gestational age, a 5-min Apgar score <7, congenital malformation and foetal distress. Results: The AYA cancer survivor group had a 9% higher risk of overall adverse birth outcomes (adjusted odds ratio, 1.09; 95% confidence interval, 1.02–1.16), especially low birth weight and preterm labour than the comparison group. The radiotherapy-only group additionally had a higher risk of foetal distress, and a 5-min Apgar score <7. Conclusion: AYA cancer survivors, especially those who have received radiotherapy, still have higher risks of adverse birth outcomes after adjusting for detailed maternal health conditions. Preconception counselling and additional surveillance may be warranted in this population.
UR - http://www.scopus.com/inward/record.url?scp=85077867870&partnerID=8YFLogxK
U2 - 10.1038/s41416-019-0712-2
DO - 10.1038/s41416-019-0712-2
M3 - Article
C2 - 31929517
AN - SCOPUS:85077867870
SN - 0007-0920
VL - 122
SP - 918
EP - 924
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 6
ER -